JP2005507947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507947A5 JP2005507947A5 JP2003541835A JP2003541835A JP2005507947A5 JP 2005507947 A5 JP2005507947 A5 JP 2005507947A5 JP 2003541835 A JP2003541835 A JP 2003541835A JP 2003541835 A JP2003541835 A JP 2003541835A JP 2005507947 A5 JP2005507947 A5 JP 2005507947A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- group
- carboxy
- optionally
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- -1 3- [6- (4-carboxy-cyclohexyl)-[1,7] naphthyridin-8-yl] -benzoic acid 4- [8- (5-fluoro-2-methoxy-phenyl)-[1,7] naphthyridin-6-yl] -cyclohexanecarboxylic acid ethyl ester Chemical compound 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- JAZMOBNQGPEOPM-UHFFFAOYSA-N 4-[8-(3-carbamoylphenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic acid Chemical compound NC(=O)C1=CC=CC(C=2C3=NC=CC=C3C=C(N=2)C2CCC(CC2)C(O)=O)=C1 JAZMOBNQGPEOPM-UHFFFAOYSA-N 0.000 claims 1
- TWWNJXWEOLLKJT-UHFFFAOYSA-N 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1C1=CC2=CC=CN=C2C(C=2C=C(C=CC=2)C#N)=N1 TWWNJXWEOLLKJT-UHFFFAOYSA-N 0.000 claims 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZHLTXMKVCCTAHU-UHFFFAOYSA-N ethyl 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylate Chemical compound C1CC(C(=O)OCC)CCC1C1=CC2=CC=CN=C2C(C=2C=C(C=CC=2)C#N)=N1 ZHLTXMKVCCTAHU-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBJPVPWHRDXZFE-UHFFFAOYSA-M potassium;4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylate Chemical compound [K+].C1CC(C(=O)[O-])CCC1C1=CC2=CC=CN=C2C(C=2C=C(C=CC=2)C#N)=N1 NBJPVPWHRDXZFE-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0126511A GB0126511D0 (en) | 2001-11-05 | 2001-11-05 | Organic compounds |
| GB0209882A GB0209882D0 (en) | 2002-04-30 | 2002-04-30 | Organic compounds |
| PCT/EP2002/012300 WO2003039544A1 (en) | 2001-11-05 | 2002-11-04 | Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005507947A JP2005507947A (ja) | 2005-03-24 |
| JP2005507947A5 true JP2005507947A5 (enExample) | 2005-11-17 |
| JP4150672B2 JP4150672B2 (ja) | 2008-09-17 |
Family
ID=26246741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541835A Expired - Lifetime JP4150672B2 (ja) | 2001-11-05 | 2002-11-04 | ナフチリジン誘導体、その製造およびそのホスホジエステラーゼイソ酵素４（ｐｄｅ４）阻害剤としての使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7273875B2 (enExample) |
| EP (1) | EP1443925B8 (enExample) |
| JP (1) | JP4150672B2 (enExample) |
| KR (1) | KR100623548B1 (enExample) |
| CN (1) | CN1298324C (enExample) |
| AR (1) | AR037517A1 (enExample) |
| AT (1) | ATE349209T1 (enExample) |
| BR (1) | BR0213877A (enExample) |
| CA (1) | CA2462211C (enExample) |
| CY (1) | CY1107532T1 (enExample) |
| DE (1) | DE60217160T2 (enExample) |
| DK (1) | DK1443925T3 (enExample) |
| ES (1) | ES2275935T3 (enExample) |
| HU (1) | HUP0402311A3 (enExample) |
| IL (2) | IL161257A0 (enExample) |
| MX (1) | MXPA04004264A (enExample) |
| MY (1) | MY130622A (enExample) |
| NO (1) | NO329093B1 (enExample) |
| NZ (1) | NZ532586A (enExample) |
| PE (1) | PE20030535A1 (enExample) |
| PL (1) | PL368286A1 (enExample) |
| PT (1) | PT1443925E (enExample) |
| RU (1) | RU2296764C2 (enExample) |
| TW (1) | TWI320784B (enExample) |
| WO (1) | WO2003039544A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| ES2251866B1 (es) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0601951D0 (en) * | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| JP2010504933A (ja) | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| AU2007342223B2 (en) | 2007-01-10 | 2011-02-24 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
| EP2332933A1 (en) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial sodium channel (ENaC) inhibitors |
| WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
| BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| ES2396023T3 (es) | 2009-01-29 | 2013-02-18 | Novartis Ag | Bencimidazoles sustituidos para el tratamiento de astrocitomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| IN2012DN01453A (enExample) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| US20110082145A1 (en) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
| AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112013000946B1 (pt) | 2010-07-14 | 2020-09-08 | Novartis Ag | Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
| TW201311149A (zh) * | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| AR089698A1 (es) | 2012-01-13 | 2014-09-10 | Novartis Ag | Compuestos heterociclicos antagonistas del receptor ip |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
| CN103969300B (zh) * | 2013-01-24 | 2016-08-17 | 湖北大学 | 一种识别cgg三核苷酸重复序列的双功能电活性探针、探针的制备及试剂盒 |
| ES2637719T3 (es) | 2013-02-13 | 2017-10-16 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor IP |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| AU2014241430B2 (en) | 2013-03-14 | 2018-04-26 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
| HK1219421A1 (zh) | 2013-03-15 | 2017-04-07 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| AU2014391610B2 (en) | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN106146491B (zh) * | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| CA3124670A1 (en) | 2018-12-28 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors |
| US20200383960A1 (en) | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
| CN110339192A (zh) * | 2019-08-22 | 2019-10-18 | 吉林大学 | 一种掌叶防己碱用于治疗急性肺损伤的实验方法 |
| KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
| EP3805206B1 (en) * | 2019-10-08 | 2026-08-05 | Novaled GmbH | Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IE903911A1 (en) * | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
| US5466697A (en) * | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
| GB9622386D0 (en) * | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| RU2174123C2 (ru) * | 1996-10-28 | 2001-09-27 | Новартис Аг | Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| JP2002114684A (ja) | 2000-10-03 | 2002-04-16 | Eisai Co Ltd | 尿路疾患治療剤 |
-
2002
- 2002-11-01 AR ARP020104187A patent/AR037517A1/es unknown
- 2002-11-01 MY MYPI20024102A patent/MY130622A/en unknown
- 2002-11-04 AT AT02787554T patent/ATE349209T1/de active
- 2002-11-04 IL IL16125702A patent/IL161257A0/xx unknown
- 2002-11-04 RU RU2004117169/04A patent/RU2296764C2/ru not_active IP Right Cessation
- 2002-11-04 EP EP02787554A patent/EP1443925B8/en not_active Expired - Lifetime
- 2002-11-04 NZ NZ532586A patent/NZ532586A/en not_active IP Right Cessation
- 2002-11-04 PL PL02368286A patent/PL368286A1/xx not_active Application Discontinuation
- 2002-11-04 WO PCT/EP2002/012300 patent/WO2003039544A1/en not_active Ceased
- 2002-11-04 MX MXPA04004264A patent/MXPA04004264A/es active IP Right Grant
- 2002-11-04 CA CA2462211A patent/CA2462211C/en not_active Expired - Lifetime
- 2002-11-04 TW TW091132476A patent/TWI320784B/zh not_active IP Right Cessation
- 2002-11-04 CN CNB028214897A patent/CN1298324C/zh not_active Expired - Lifetime
- 2002-11-04 JP JP2003541835A patent/JP4150672B2/ja not_active Expired - Lifetime
- 2002-11-04 DE DE60217160T patent/DE60217160T2/de not_active Expired - Lifetime
- 2002-11-04 KR KR1020047006772A patent/KR100623548B1/ko not_active Expired - Fee Related
- 2002-11-04 US US10/494,223 patent/US7273875B2/en not_active Expired - Lifetime
- 2002-11-04 PT PT02787554T patent/PT1443925E/pt unknown
- 2002-11-04 PE PE2002001073A patent/PE20030535A1/es not_active Application Discontinuation
- 2002-11-04 HU HU0402311A patent/HUP0402311A3/hu unknown
- 2002-11-04 ES ES02787554T patent/ES2275935T3/es not_active Expired - Lifetime
- 2002-11-04 DK DK02787554T patent/DK1443925T3/da active
- 2002-11-04 BR BR0213877-8A patent/BR0213877A/pt not_active Application Discontinuation
-
2004
- 2004-04-01 IL IL161257A patent/IL161257A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042097A patent/NO329093B1/no not_active IP Right Cessation
-
2007
- 2007-03-06 CY CY20071100316T patent/CY1107532T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2462211A1 (en) | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors | |
| TWI334354B (en) | Use for treating atherosclerosis, dyslipidemias and related conditions | |
| CA2832996C (en) | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors | |
| EP3760629A1 (en) | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | |
| WO2006124490A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| WO2005007081A3 (en) | Compounds and methods for delivery of prostacyclin analogs | |
| JP2013542261A5 (enExample) | ||
| JP2017527604A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| CN1444478A (zh) | 塞利克西组合物在快速缓解疼痛中的用途 | |
| CA2902987A1 (en) | Benzyl-substituted pyrazolopyridines and use thereof | |
| JP2010516701A5 (enExample) | ||
| JP2024540525A5 (enExample) | ||
| WO2012075253A3 (en) | Pharmaceutical compositions | |
| JP2010516700A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| CA2626477A1 (en) | Dicarboxylic acid derivatives and their use | |
| JP2009513713A5 (enExample) | ||
| WO2023169572A1 (zh) | 一种三嗪类化合物、其中间体、其制备方法及其用途 | |
| JP2011088923A (ja) | ピラゾロナフチリジン誘導体 | |
| JP7016853B2 (ja) | ｓＧＣ刺激剤のリンプロドラッグ | |
| JP2005502636A5 (enExample) | ||
| SK4222001A3 (en) | 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation | |
| WO2007080324A3 (fr) | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. | |
| JP2012528185A5 (enExample) |